328 related articles for article (PubMed ID: 32390710)
1. Nrf2 activation through the inhibition of Keap1-Nrf2 protein-protein interaction.
Lee S; Hu L
Med Chem Res; 2020 May; 29(5):846-867. PubMed ID: 32390710
[TBL] [Abstract][Full Text] [Related]
2. Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents.
Abed DA; Goldstein M; Albanyan H; Jin H; Hu L
Acta Pharm Sin B; 2015 Jul; 5(4):285-99. PubMed ID: 26579458
[TBL] [Abstract][Full Text] [Related]
3. Updated research and applications of small molecule inhibitors of Keap1-Nrf2 protein-protein interaction: a review.
Zhuang C; Miao Z; Sheng C; Zhang W
Curr Med Chem; 2014; 21(16):1861-70. PubMed ID: 24533814
[TBL] [Abstract][Full Text] [Related]
4. CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-κB activation.
Lu MC; Zhao J; Liu YT; Liu T; Tao MM; You QD; Jiang ZY
Redox Biol; 2019 Sep; 26():101266. PubMed ID: 31279986
[TBL] [Abstract][Full Text] [Related]
5. Identification of compounds that inhibit the binding of Keap1a/Keap1b Kelch DGR domain with Nrf2 ETGE/DLG motifs in zebrafish.
Raghunath A; Nagarajan R; Sundarraj K; Palanisamy K; Perumal E
Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):259-270. PubMed ID: 30861618
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions.
Lu MC; Shao HL; Liu T; You QD; Jiang ZY
Eur J Med Chem; 2020 Dec; 207():112734. PubMed ID: 32866756
[TBL] [Abstract][Full Text] [Related]
7. Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor.
Yasuda D; Yuasa A; Obata R; Nakajima M; Takahashi K; Ohe T; Ichimura Y; Komatsu M; Yamamoto M; Imamura R; Kojima H; Okabe T; Nagano T; Mashino T
Bioorg Med Chem Lett; 2017 Nov; 27(22):5006-5009. PubMed ID: 29037947
[TBL] [Abstract][Full Text] [Related]
8. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
9. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
Jiang ZY; Lu MC; You QD
J Med Chem; 2016 Dec; 59(24):10837-10858. PubMed ID: 27690435
[TBL] [Abstract][Full Text] [Related]
11. Recent progress in the development of small molecule Nrf2 activators: a patent review (2017-present).
Zhou H; Wang Y; You Q; Jiang Z
Expert Opin Ther Pat; 2020 Mar; 30(3):209-225. PubMed ID: 31922884
[No Abstract] [Full Text] [Related]
12. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
[TBL] [Abstract][Full Text] [Related]
13. Structural and mechanistic insights into the Keap1-Nrf2 system as a route to drug discovery.
Madden SK; Itzhaki LS
Biochim Biophys Acta Proteins Proteom; 2020 Jul; 1868(7):140405. PubMed ID: 32120017
[TBL] [Abstract][Full Text] [Related]
14. The Keap1-Nrf2 system as an in vivo sensor for electrophiles.
Uruno A; Motohashi H
Nitric Oxide; 2011 Aug; 25(2):153-60. PubMed ID: 21385624
[TBL] [Abstract][Full Text] [Related]
15. Pterostilbene-mediated Nrf2 activation: Mechanistic insights on Keap1:Nrf2 interface.
Bhakkiyalakshmi E; Dineshkumar K; Karthik S; Sireesh D; Hopper W; Paulmurugan R; Ramkumar KM
Bioorg Med Chem; 2016 Aug; 24(16):3378-86. PubMed ID: 27312421
[TBL] [Abstract][Full Text] [Related]
16. The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases.
Deshmukh P; Unni S; Krishnappa G; Padmanabhan B
Biophys Rev; 2017 Feb; 9(1):41-56. PubMed ID: 28510041
[TBL] [Abstract][Full Text] [Related]
17. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.
Lu MC; Yuan ZW; Jiang YL; Chen ZY; You QD; Jiang ZY
Mol Biosyst; 2016 Apr; 12(4):1378-87. PubMed ID: 26935067
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.
Taguchi K; Motohashi H; Yamamoto M
Genes Cells; 2011 Feb; 16(2):123-40. PubMed ID: 21251164
[TBL] [Abstract][Full Text] [Related]
19. Polar Recognition Group Study of Keap1-Nrf2 Protein-Protein Interaction Inhibitors.
Lu MC; Tan SJ; Ji JA; Chen ZY; Yuan ZW; You QD; Jiang ZY
ACS Med Chem Lett; 2016 Sep; 7(9):835-40. PubMed ID: 27660687
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
